Mitochon Technologies was founded in 2018 with the specific purpose of developing new therapies for mitochondrial diseases. The lead molecule of the company’s late-stage portfolio – BGP-15 – was licensed from N-Gene Inc. for a number of indications. Multiple phase 2 studies are currently being initiated and several preclinical projects are ongoing in various diseases. First marketing authorization is expected in 2022.

Laszlo Bicskei, the CEO of the company received an M.Sc. in Biomedical Engineering at Semmelweis University and an M.Sc. in Computer Sciences with a specialisation in Artificial Intelligence at the Budapest University of Technology and Economics. Early in his career he was involved in various research projects at the Institute of Experimental Medicine of the Hungarian Academy of Sciences and developed biomedical algorithms at Innomed Medical Inc. and General Electric Healthcare. Later he received a Marie Curie fellowship at University College London, where he worked as a Computational Neuroscience researcher for 4 years. Later he joined a leading international pharmaceutical consultancy in London as a Management Consultant, where he led numerous local and global engagements working with the largest pharmaceutical companies across multiple therapy areas. In 2016, he joined X-Ventures Venture Capital to manage the fund’s life sciences investments and additionally to his current role at Mitochon Technologies, he is acting as the CEO of Humeltis Ltd, an innovative biotechnology company providing personalised cancer therapy recommendation for patients using propriatery 3D tissue engineering technology.

Our Advisory Team

Kalman Tory, M.D., Ph.D., our medical advisor received his M.D. and Ph.D. degrees at Semmelweis University, Budapest. After a short clinical training he joined the Institute of Drug Research, Budapest and took part in the development of three new antitumor drug candidates. He had a fellowship at the Laboratory of Immunobiology at NCI, Frederick, MD, US, then at the same institute he took part in the Human Genome project as a group leader for three more years. He worked on the building of a genetic map of human chromosome 3, furthermore on the cloning and analysis of the von Hippel-Lindau (VHL) tumor suppressor gene. He continued his work on VHL and renal cancer biology at DKFZ, Heidelberg and RWTH, Aachen, Germany. After returning to Hungary, he joined Biorex Ltd and took part in the pharmacological development of new antidiabetic agents. Later he served as a senior adviser at Sanofi for one year. He moved to N-Gene RD Ltd. where he took part in the development of hydroxylamine type drug candidates in various therapeutic directions. He has published more than 60 papers in peer-reviewed journals, and he is the inventor of several pharmacological patents.